Hormone Therapy Resource Information

At LoveJoy Hormone Clinic, we are experts in the field of Hormone Therapy. Especially in Bioidentical Hormone Replacement Therapy (BHRT).  You have a choice of how you learn more about hormone therapy in your own life.  You have some choices: 

  • Speak with your primary care provider (PCP) about hormones
  • Do your own research on the web
  • Talk to your friends about what they know
  • Visit with an expert in hormone therapy with thousands of patients (LoveJoy).
Hormone Testing

Time to Get Educated

Below are some very informative research articles to help you become “informed.” The more you understand hormone imbalance and how it can effect your life in many ways, the better you can make intelligently informed decisions.

We want you to understand as much as possible before your first consultation with us. The transfer of knowledge and once you are on LoveJoy BHRT, then you will feel comfortable knowing why and how our therapy services are making your life better.

Please review the articles below. Here at LoveJoy, we want to be as transparent about hormone therapy as we can. We are in this medical business to help as many people as we can. We are scientific in our approach and these articles will help you see that.

Postmenopausal Hormone Therapy for Cardiovascular Health

This article describes studies on how Hormone Therapy impacts Cardiovascular health. The studies concluded that Post-Menopausal Hormone Therapy is safe and beneficial and is used to treat symptoms, strengthen bones, improve quality of life, and preserve Cardiovascular health through post-menopausal years, augmenting standard cardiovascular disease risk reduction measures.
LINK: https://heart.bmj.com/content/107/14/1115

Postmenopausal Estrogen Therapy Route of Administration and Risk of Venous Thromboembolism

This article by The American College of Obstetricians and Gynecologists explains how Menopausal symptoms and related disorders lead women to seek postmenopausal ET and HT prescriptions. The probability of venous thromboembolism increases with age and the presence of additional risk factors. Before prescribing HT or ET, the prescriber should carefully assess patients’ personal and family history. When prescribing ET, consider the thrombosis-sparing properties of transdermal forms. Weigh the risks against the benefits and counsel patients accordingly.*
LINK: https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2013/04/postmenopausal-estrogen-therapy-route-of-administration-and-risk-of-venous-thromboembolism

Incidence of invasive breast cancer in women treated with testosterone implants: a prospective 10-year cohort study

This article by BMC Cancer reviews a 10-year cohort study on the effects of long-term therapy using subcutaneous testosterone implants. At the end of the 10-year study, it was concluded that long-term therapy with subcutaneous testosterone implants or testosterone combined with anastrozole did not increase the incidence of invasive breast cancer.
LINK: https://bmccancer.biomedcentral.com/articles/10.1186/s12885-019-6457-8

In Defense of Progesterone: A Review of the Literature

This article discusses a meta-analysis of 3 studies that concluded how Progesterone is linked to a lower risk of breast cancer compared to synthetic progestins. It may also lower the risk of uterine and colon cancers, and help treat other cancers like ovarian, melanoma, mesothelioma, and prostate. Additionally, Progesterone may prevent cardiovascular disease and treat neurodegenerative conditions such as stroke and traumatic brain injury. Physicians can confidently prescribe natural progesterone, as it is not associated with causing breast cancer, but rather has protective and preventative effects.
LINK: https://pubmed.ncbi.nlm.nih.gov/29055286/

Estradiol-based Postmenopausal Hormone Therapy and Risk of Cardiovascular and all-cause Mortality

This article covers the studies on how Hormone Therapy (HT) users have a lower risk of Coronary Heart Disease (CHD) and stroke-related deaths, ranging from 18% to 54% and 18% to 39%, respectively. The risk of all-cause mortality is also reduced by 12% to 38%, almost linearly with the duration of exposure. These risk reductions are similar for women who initiate HT before the age of 60, and for those who initiate HT at the age of 60 or older. For every 1,000 women who use HT for at least 10 years, there are 19 fewer CHD-related deaths and 7 fewer stroke-related deaths.
LINK: https://pubmed.ncbi.nlm.nih.gov/25803671/

Breast Cancer Incidence Reduction in Women Treated with Subcutaneous Testosterone: Testosterone Therapy and Breast Cancer Incidence Study

This article by Eur J Breast Health concludes that The Testosterone Therapy and Breast Cancer Incidence Study conducted over 9 years showed that Testosterone (T) and Testosterone and Estrogen (T/E) hormone pellet implants reduced Instances of Breast Cancer (IBC) by 35.5%. Since 1937, subcutaneous T implants have been used to treat T deficiency in women and IBC as well. T is now recognized as a crucial hormone in women, and by age 40, women’s T production is reduced by 50% and they mostly become T deficient. An International Consensus Group unanimously agreed in 2018 that T was the most important hormone for women.
LINK: https://eurjbreasthealth.com/archives/archive-detail/article-preview/breast-cancer-ncidence-reduction-in-women-treated-/47126

Testosterone Therapy in Women: Myths and Misconceptions

This article by El Sevier explains how adequate testosterone is necessary for physical, mental, and emotional health in both genders. This article dispels the myths and misconceptions about testosterone and its’ therapy in females and will enable physicians to provide evidence-based recommendations and appropriate treatment.
LINK: https://www.sciencedirect.com/science/article/pii/S0378512213000121

ASCO Breast: Implants May Quell Hormone Deficiency

This article by MedPage Today discusses a clinical series that revealed that a testosterone implant placed under the skin can potentially alleviate hormone-deficiency symptoms in breast cancer survivors without causing an increase in estradiol levels. The data suggests that testosterone may have positive effects on breast tissue, which has led to a high number of referrals from oncologists.
LINK: https://www.drmichaelschoenwalder.com/patienteducation/articles/ASCO%20Breast%20-%20Implants%20May%20Quell%20Hormone%20Deficiency.pdf

Hormone Therapy with Pellet Implants

This article explains how continuous testosterone alone, delivered by a subcutaneous implant, was effective for the relief of hormone deficiency symptoms in both pre-and post-menopausal patients and proves that pellets are superior to oral and topical hormone therapy.
LINK: https://hormonebalance.org/userfiles/file/DATA%20Pellet%20implants%206%2011%5B2%5D.pdf

Testosterone Therapy and Cardiovascular Risk: Advances and Controversies

This article by the Mayo Clinic addresses no convincing evidence of increased cardiovascular risks with testosterone therapy. On the contrary, there appears to be a strong beneficial relationship between normal testosterone levels and cardiovascular health that has not yet been widely appreciated.
LINK: Testosterone Therapy and Cardiovascular Risk: Advances and Controversies – Mayo Clinic Proceedings

Efficacy of subcutaneous testosterone on menopausal symptoms in breast cancer survivors

This article explains how when Testosterone and Anastrozole together are delivered through a subcutaneous implant, they provide effective menopausal symptom relief for breast cancer survivors. It is concluded that the therapy is safe, and it could be recommended to women who have a history of breast cancer or are at an increased risk of developing the disease and are experiencing hormone deficiency symptoms.
LINK: https://www.researchgate.net/publication/265784789_Efficacy_of_subcutaneous_testosterone_on_menopausal_symptoms_in_breast_cancer_survivors

Can Estrogen Prevent Alzheimer's Disease in Women? A Window of Opportunity

This article by Clinical Advisor addresses how Alzheimer’s disease (AD) affects women more than men. Research suggests that estrogen and Estrogen hormone therapy (EHT) may prevent AD. A safe window for EHT initiation may exist around the onset of menopause. Further research is needed to determine factors like efficacy, dosing, route of administration, and duration.
LINK: https://www.clinicaladvisor.com/home/topics/neurology-information-center/can-estrogen-prevent-alzheimers-disease-women-window-opportunity/

Estrogen-Only Hormone Replacement Therapy After Oophorectomy in Women with BRCA1 Mutation Doesn’t Seem to Increase Breast Cancer Risk

According to the research described in this article, it has been concluded that the use of estrogen after the removal of ovaries does not increase the risk of breast cancer among women with a BRCA1 mutation. This should reassure BRCA1 mutation carriers considering preventive surgery that HRT is safe. However, the possible adverse effect of progesterone-containing HRT still requires further study.
LINK: https://www.breastcancer.org/research-news/hrt-and-risk-for-brca1-mutation-after-ooph

Hormone Replacement Therapy in Carriers of the BRCA1 Mutation

The article by Consult QD addresses a case-control study from 2016 that was conducted to assess the impact of hormone replacement therapy on postmenopausal BRCA1 mutation carriers with invasive breast cancer (cases) and those without a history of breast cancer (controls). The study included 432 participants in each group. The results of the study showed no significant difference in breast cancer risk between hormone replacement therapy users and nonusers.
LINK: https://consultqd.clevelandclinic.org/hormone-replacement-therapy-in-carriers-of-the-brca1-mutation/#:~:text=Results%20showed%20no%20difference%20in,replacement%20therapy%20users%20and%20nonusers

Hormone Replacement Therapy in BRCA Mutation Carriers and Risk of Ovarian, Endometrial, and Breast Cancer: A Systematic Review

Journal of Cancer Research and Clinical Oncology wrote an article explaining that limited data suggests that HRT doesn’t increase cancer risk in BRCA mutation carriers. RRBSO shouldn’t be delayed to avoid HRT. Adequate HRT should be given after RRBSO to prevent chronic diseases from low estrogen levels.
LINK: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8164576/

Scroll to Top